Clinical Trial: CW-301 FIH Study of CAN016

U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07664150) titled 'CW-301 FIH Study of CAN016' on June 14.

Brief Summary: A Phase I/II, Open-Label, Non-Randomized, Multi-Centre First-in-Human Study of CAN016 in Patients with Advanced Solid Tumors

Study Start Date: June 18

Study Type: INTERVENTIONAL

Condition: Patients With Advanced Solid Tumors

Intervention: DRUG: CAN016

CAN016 will be administered intravenously into each patient on Day 1 of Cycle 1. Patients will continue to receive CAN016 Q3W until unacceptable toxicity, progressive disease, or withdrawal of consent, death, lost to F/U, or other discontinuation criteria is met.

DRUG: CAN016

an initial dose of CAN016 0.75 mg/kg will be ad...